NCT05149170

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Radiotherapy With Inductive and Concurrent Anti-PD-1 Antibody in Early-stage Low-risk Extranodal NK/T Cell Lymphoma, Nasal Type: A Multi-center Phase II Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-risk extranodal NK/T cell lymphoma, nasal type

Conditions

• Early-stage
• Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

Type	Name	Description
DRUG	Anti-PD-1 monoclonal antibody	inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT

Timeline

• Start date: 2021-10-01
• Primary completion: 2022-09-30
• Completion: 2024-09-30
• First posted: 2021-12-08
• Last updated: 2021-12-08

Locations

1 site across 1 country: China